Abstract
Acne unfiltered: expert discussion on stigma and solutions with Alison M Layton, Christine Bundy, Ncoza Dlova, Jacek Szepietowski and Elisete Crocco. The video is playable in the HTML version. Acne is a common, inflammatory skin disease with global prevalence approaching 9% and affects many millions of people worldwide.1 Although frequently dismissed as a transient ‘rite of passage’ in teenagers who are most frequently affected, acne can persist for many years and aligns with the World Health Organization’s criteria of a chronic disease.2 Acne may also lead to long-standing hyperpigmentation and indelible scarring. These sequelae generate a profound, long-lasting psychosocial burden which is often worse than that caused by the original acne and may extend well beyond the course of the active acne lesions.3 Patients often perceive the clinical sequelae as more distressing than the active acne. The clinical sequelae are notoriously hard to treat, amplify psychosocial burden and are frequently more pronounced in skin of colour. Acne commonly leads to low self-esteem and anxiety. The distress caused by acne has been linked to self-harm. This negative burden has been reported widely across all cultures and geographical areas. Some people with acne will develop clinical depression, suicidal ideation and, rarely, suicide has been reported.4,5 Persistent worry about appearance is reported widely across all age groups with acne but especially with adolescents and young adults, who represent a vulnerable population undergoing a period of physical and psychological transition.6 People with acne consistently report feeling viewed less favourably by peers and adults and rate their changed appearance as the most important compromising consequence of acne as a result of stigmatization. This view is supported with clear evidence that people with acne and acne-induced scarring are perceived less favourably by their peers and society.7–9 Appearance-related concerns are the dominant driver of distress, and acne-related appearance anxiety impairs social participation, sporting activities, intimate relationships, and schooling or work performance. Many people with acne withdraw socially, avoid dating or pursuing job opportunities, and report sleep disturbance and reduced life satisfaction. Patients with darker skin tones frequently experience a ‘triple burden’: active acne, persistent hyperpigmentation and keloid/atrophic scarring. Acne-induced pigmentation is often the primary concern in skin of colour and this is frequently under-recognized. Like acne-induced scarring, pigment change can prove challenging to treat and is associated with inflammation; therefore, early access to effective treatments aimed at reducing the inflammatory component is crucial as a means of avoiding these burdensome sequelae. Socioeconomic barriers, limited access to dermatological care, and reliance on unregulated products increase the risk of delayed effective treatment and can result in more severe clinical and psychosocial sequelae. Preventing inflammation, discouraging skin manipulation, and treating active disease promptly has the potential to reduce the risk of scarring, pigmentation and long-term psychosocial sequelae. Integrating routine screening for distress, anxiety and suicidal ideation into dermatology visits, providing or signposting psychological support and tailored interventions for skin of colour all contribute to achieving positive outcomes. Resource constraints, differences in health systems, unfounded cultural beliefs about acne (e.g. links to hygiene) and variable patient support infrastructures all influence behaviours and, in turn, management outcomes. Social media plays an important role in influencing beliefs and behaviours and frequently provides misinformation to people with acne. Diverse cultures may have different influencers such as accessible and affordable remedies provided by nonmedical providers, such as use of steroids as skin-lightening agents, which can lead to harmful self-care contributing to worsening disease. Public and clinician education to correct myths, reduce stigma and raise awareness that acne can be life-ruining for some should all contribute to comprehensive care. School- and community-based antibullying campaigns and short, narrative-based interventions have the potential to shift peer attitudes. However, there is a paucity of these schemes and limited access to patient support groups globally. Resources informed by people with lived experience and brief, clinic-friendly instruments to measure psychosocial impact that include assessment of appearance-related concerns should all be adopted when managing acne across diverse populations. In conclusion, acne reflects a very common, chronic condition with substantial physical, psychosocial and economic burden. Although acne is rarely life threatening it is frequently life ruining and should not be underestimated. Addressing appearance-related worries, stigma and bullying, with effective education to influence beliefs and behaviours, alongside timely management, should be central to a strategic approach aimed at reducing both clinical and psychosocial burden globally. Alison M. Layton (Writing—original draft [lead]), Christine Bundy (Writing—review & editing [equal]), Ncoza Cordelia Dlova (Writing—review & editing [equal]), Jacek Szepietowski (Writing—review & editing [equal]), and Elisete Crocco (Writing—review & editing [equal]). The Virtual Roundtable was sponsored by Eucerin. A.M.L. declares grant funding awarded to her employing organization to deliver National Institute for Health Research portfolio studies, including a Health Technology Assessment grant, a British Skin Foundation grant and a Medical Research Council grant; in addition, she has received honoraria for acting as a consultant, attending advisory boards or providing unrestricted presentations involving educational events and national and international meetings from Alliance, Almirall, Beiersdorf, Eligo, Galderma Pharma, Glenmark, La Roche-Posay, LEO Pharma, L’Oréal, Vakona and Vitrias. The other authors declare no conflicts of interest. There are no new data associated with this article. Not applicable. Not applicable.